Financhill
Back

Agios Pharmaceuticals Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals Price Quote

$29.41
-0.02 (1.31%)
(Updated: April 19, 2024 at 5:51 AM ET)

Agios Pharmaceuticals Key Stats

Sell
29
Agios Pharmaceuticals (AGIO) is a Sell

Day range:
$29.03 - $29.90
52-week range:
$19.80 - $35.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
61.06
P/B ratio:
2.04%

Volume:
432K
Avg. volume:
601.6K
1-year change:
30.86%
Market cap:
$1.7B
Revenue:
$26.8M
EPS:
$-6.34

How Much Does Agios Pharmaceuticals Make?

Is Agios Pharmaceuticals Growing As A Company?

  • What Is Agios Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.65%
  • What Is Agios Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Agios Pharmaceuticals Stock Price Performance

What Is Agios Pharmaceuticals 52-Week High & Low?

Agios Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Agios Pharmaceuticals?

Is Agios Pharmaceuticals Cash Flow Positive?

  • What Is AGIO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$296.1M
  • What Is Agios Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $5.4M
  • What Is Agios Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $239.6M

Agios Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    AGIO return on invested capital is -36.68%
  • What Is Agios Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -32.48%
  • What Is AGIO Return On Equity?
    ROE is a measure of profitability and is -36.68%

Agios Pharmaceuticals Earnings Date & Stock Price

Agios Pharmaceuticals Competitors

  • Who Are Agios Pharmaceuticals's Competitors?
    Below is a list of companies who compete with Agios Pharmaceuticals or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Blueprint Medicines Corp (BPMC)
    • Corcept Therapeutics Inc (CORT)
    • Ionis Pharmaceuticals Inc (IONS)
    • Madrigal Pharmaceuticals Inc (MDGL)

Agios Pharmaceuticals Dividend Yield

Data Unavailable

Agios Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -4.99%
Revenue: 64.8% -10.36%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 40.67
Upside from Last Price: 38.18%

Major Shareholders

  • How many AGIO shares are owned by institutional investors?
    93.6M AGIO shares are owned by institutional investors
  • How many AGIO shares are owned by insiders?
    1.2M AGIO shares are owned by insiders